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The Neuronal ceroid lipofuscinoses (NCLs) are a group of recessive disorders of 25 
childhood with overlapping symptoms including vision loss, ataxia, cognitive regression and 26 
premature death. 14 different genes have been linked to NCLs (CLN1-CLN14), but the functions 27 
of the proteins encoded by the majority of these genes have not been fully elucidated. Mutations 28 
in the CLN5 gene are responsible for the Finnish variant late-infantile form of NCL (Finnish 29 
vLINCL). CLN5 is translated as a 407 amino acid transmembrane domain containing protein that 30 
is heavily glycosylated, and subsequently cleaved into a mature soluble protein. Functionally, 31 
CLN5 is implicated in the recruitment of the retromer complex to endosomes, which is required 32 
to sort the lysosomal sorting receptors from endosomes to the trans-Golgi network. The 33 
mechanism that processes CLN5 into a mature soluble protein is currently not known. Herein, 34 
we demonstrate that CLN5 is initially translated as a type II transmembrane protein and 35 
subsequently cleaved by SPPL3, a member of the SPP/SPPL intramembrane protease family, 36 
into a mature soluble protein consisting of residues 93-407. The remaining N-terminal fragment 37 
is then cleaved by SPPL3 and SPPL2b and degraded in the proteasome. This work further 38 
characterizes the biology of CLN5 in the hopes of identifying a novel therapeutic strategy for 39 




 CLN5 is initially translated as a type II integral membrane protein 44 
 CLN5 is cleaved after residue 92 45 
 CLN5 cleavage is mediated by SPPL3 46 






CLN5, Signal Peptide Peptidase-like proteases, Neuronal Ceroid Lipofuscinosis, endosomes, 50 




 Neuronal ceroid lipofuscinoses (NCLs) are recessive disorders that are the most common 55 
neurodegenerative diseases of childhood [1].  Common symptoms of NCLs include gradual 56 
dementia, progressive vision loss, ataxia and seizures and they almost always result in premature 57 
death [2]. At the cellular level, NCL patients present an accumulation of autofluorescent 58 
lipopigments in cellular subcompartments [3]. Germline mutations in 14 different genes (CLN1-59 
CLN14) have been shown to lead to human disease [4], but the exact function of many of the 60 
proteins encoded by these genes remains unknown or poorly understood hampering the 61 
development of therapies. 62 
 CLN5 is encoded on chromosome 13q21–q32 [5, 6] and produces a 407 amino acid 63 
protein of a predicted molecular mass of 46 kDa that is heavily glycosylated [7-9]. Mutations in 64 
the CLN5 gene were first identified in 18 families in Finland thus naming this variant of NCL: 65 
late-infantile Finnish variant (Finnish vLINCL) [10, 11]. Since the initial identification of the 66 
disease and mapping of the gene responsible, patients with NCL derived from a mutation in the 67 
CLN5 gene have been found in various regions around the globe [9, 12]. 68 
Several studies have shown that CLN5 localizes to the lysosomal compartment [8, 13] 69 
but little data is available as to the function of CLN5. We have shown a role for CLN5 in 70 
controlling the itinerary of the lysosomal sorting receptors by regulating retromer recruitment at 71 
late endosomes [14]. Indeed, we found that CLN5 was required for the activation and 72 
localization of Rab7 and subsequently, the recruitment of retromer to endosomal membranes. 73 
Furthermore, we found that in CLN5-depleted cells, both sortilin and the cationic independent 74 
mannose-6-phosphate receptor (CIMPR) were degraded in lysosomes, a similar phenotype as 75 
observed in retromer-depleted cells [15, 16]. Although CLN5 plays a role in the efficient 76 
endosome-to-trans Golgi Network (TGN) trafficking of these receptors, there is still uncertainty 77 
regarding the characterization of the protein. 78 
Most prediction tools suggest that CLN5 could have at least one transmembrane domain and 79 
experimental evidence supports this [17-19], while other studies have shown that it is a soluble protein 80 
[19, 20]. A more recent study showed that CLN5 has one transmembrane domain and that the soluble 81 
form of the protein was potentially membrane anchored [21]. It is clear that in lysosomes, CLN5 is a 82 
soluble protein within the lumen of that organelle [8, 13]. In vitro experiments have suggested that CLN5 83 
could have 4 different initiator sites [13]. However, it appears that regardless of the site used, CLN5 is 84 
cleaved around residue 96 to produce the mature soluble protein [8]. The mechanism that cleaves CLN5 85 
into a soluble protein has not been identified. Signal Peptide Peptidase (SPP) and its homologues the 86 
Signal Peptide Peptidase-like proteases (SPPL) are intramembrane aspartyl proteases known to cleave a 87 
variety of type II transmembrane proteins including TNF [22, 23], invariant chain [24], British dementia 88 
protein-2 [25] and foamy virus envelope protein [26]. So far 5 members of the SSPP/SPPL family have 89 
been identified in the mammalian genome (SPP, SPPL2a, SPPL2b, SPPL2c and SPPL3) that all share a 90 
common conserved catalytic motif of GxGD [27]. In this work, we found that CLN5 is produced as a type 91 
II transmembrane domain protein and cleaved by a member of the SPP/SPPL after residue 92 to produce 92 
a soluble lysosomal protein (residues 93 - 407). 93 
 94 





Antibodies, cDNA constructs and other reagents 97 
 98 
All reagents, unless specified, were purchased from Fisher Scientific (Ottawa, ON). The 99 
HA-CLN5 and CLN5-HA constructs were purchased from Genecopoeia (Germantown, MD) and 100 
sequenced to ensure accuracy. The CLN5Y392* and CLN5W75* mutants were generated using the 101 
QuikChange II XL Mutagenesis kit (Stratagene, Mississauga, ON) to introduce a stop codon (*). 102 
The prosaposin-CLN5 chimera was engineered by cutting PSAP-myc [28] with NheI and 103 
inserting residues 94 - 407 of CLN5. The following mouse monoclonal antibodies were used: 104 
anti-hemagglutinin (anti-HA) antibody (MMS-101P, Cedarlane Laboratories, Burlington, ON); 105 
anti-Lamp-2 antibody (ab25631, Abcam, Cambridge, MA); anti-EEA1 antibody (610417, BD 106 
Bioscience, Mississauga, ON). The following rabbit polyclonal antibodies were used: anti-107 
Lamp2 (L0668, Sigma-Aldrich, Oakville, ON); anti-HA antibody (ab20084, Abcam), anti-108 
calnexin (ADI-SPA-865, Cedarlane Laboratories). Monoclonal anti-SPPL3 antibody was 109 
previously described [26]. Goat polyclonal anti-CLN5 antibody (sc-49928, Santa Cruz 110 
Biotechnology, Santa Cruz, CA). Rabbit monoclonal anti-CLN5 antibody (ab170899, Abcam). 111 
Anti-mouse monoclonal and anti-goat polyclonal antibodies conjugated to AlexaFluor 488 and 112 
AlexaFluor 594 used for immunofluorescence were obtained from Life Technologies 113 
(Burlington, ON). The protease inhibitor cocktail was purchased from Sigma-Aldrich (Oakville, 114 
ON). ENDO H and PNGase F were obtained from New England Biolabs (Whitby, ON). 115 
Leupeptin, pepstatin, E64 were purchased from Sigma-Aldrich (Oakville, ON) and (Z-LL)2-116 




HeLa, HEK293T and COS-7 cells were cultured in DMEM containing L-glutamine (Life 121 
Technologies, Burlington ON) supplemented with 10% Fetal Bovine Serum (FBS), 5% 122 
penicillin/streptomycin and maintained in 5% CO2 at 37 °C. Cells were transfected using 1 µg of 123 
DNA per 10-cm2 plate with Lipofectamine LTX Transfection Reagent (Life Technologies, 124 
Burlington ON) following the manufacturer’s protocol or using linear 25kDa polyethylenimine 125 
(Polysciences, Inc., Warrington, PA) as previously described [29]. RNAi of SPPL3 was 126 
previously described [26]. Briefly, siGENOME SMARTpool siRNAs targeting human SPPL3 127 
(M-006042-02-0005) and controls were purchased from Dharmacon. siRNAs were transfected 128 
using Lipofectamine RNAiMAX per manufactureres instructions (Invitrogen). Cells were 129 
analyzed on day 4 or 5 post-transfection. 130 
 131 
Membrane separation Assay 132 
 133 
24 hours post-transfection, cells were collected, snap frozen with liquid nitrogen and 134 
allowed to thaw at room temperature. Samples were resuspended in buffer 1 (0.1 M Mes-NaOH 135 
pH 6.5, 1 mM MgAc, 0.5 mM EGTA, 200 µM sodium orthovanadate, 0.2 M sucrose) and 136 
centrifuged at 10 000 g for 5 min at 4°C. The supernatant containing cytosolic proteins was 137 
collected (C, cytosolic fraction) and the pellet was resuspended in buffer 2 (50 mM Tris, 150 138 
mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100) and spun at 10 000 g for 5 min at 4 °C. 139 
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The supernatant containing membrane proteins was collected (M, membrane fraction) for further 140 
analysis [30].  141 
 142 
Sodium carbonate extraction 143 
 144 
24 hours post-transfection, cells were collected and resuspended in ice-cold 0.1 M 145 
sodium carbonate at pH 11.5. Cells were passed 10 times through a 23G syringe and the samples 146 
incubated on ice for 30 min.  Samples were then centrifuged at 100 000 g for 1 hr at 4 °C. The 147 
supernatant containing soluble proteins was collected and the pellet containing transmembrane 148 
proteins was resuspended in ice-cold 0.1 M sodium carbonate at pH 11.5. Samples were then 149 
analyzed by Western blot. 150 
 151 
Membrane Protein Topology 152 
 153 
24 hours post-transfection, cells were split into 3 groups. In group 1, the cells were lysed 154 
in ice-cold TNE (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5% Triton X-100) 155 
containing protease inhibitors. In group 2, cells were treated with 20 mM digitonin in KHM 156 
buffer (110 mM potassium acetate, 20 mM HEPES and 2mM MgCl2) on ice for 10 min prior to 157 
lysis in TNE. In group 3, cells were treated with digitonin followed by a 30 min treatment with 158 
trypsin (1/30 dilution of 0.25% Trypsin-EDTA (Life Technologies, Oakville ON) solution 159 
diluted in KHM) on ice prior to lysis in TNE.  160 
 161 
Purification of CLN5 for mass spectrometry analysis 162 
 163 
HEK 293T cells were seeded in 5 x 15 cm dishes and transfected with a plasmid coding 164 
for CLN5-HA. 24 hours post- transfection, cells were treated with 5 mM sodium butyrate for 24h 165 
to increase protein expression. Cells were then washed with PBS and detached with PBS/EDTA 166 
(5 mM) and lysed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% 167 
Triton X-100, 0.1% SDS) containing protease inhibitors for  ̴ 2 hours at 4 °C under gentle 168 
agitation. The lysates were clarified by centrifugation at 14 000 rpm for 30 minutes at 4 oC and 169 
the supernatant was precleared with protein-G sepharose beads for 1h. A monoclonal antibody 170 
against the HA epitope and protein-G sepharose were added to the supernatant followed by an 171 
overnight incubation at 4 oC. The precipitate was then washed five times in lysis buffer and the 172 
proteins eluted 1 h at room temperature in 50 µl of 2X SDS-PAGE loading buffer (125 mM Tris-173 
HCl, pH 6.5, 5% SDS, 20% glycerol, 0.2% bromophenol blue, 10% β-mercaptoethanol). 174 
Proteins were then resolved on SDS-PAGE and the gel colored with coomassie blue. The band 175 
with a molecular weight corresponding to mature CLN5 was cut and sent for mass spectrometry 176 
analysis to the Proteomics facility at the Institute for Research in Immunology and Cancer (IRIC) 177 
where LC-MS/MS was performed. The results were analysed using Scaffold 4 software. 178 
Western blotting 179 
 180 
HeLa cells seeded in 6-well plates were transfected with the indicated plasmids. 181 
Approximately 24 hours after transfection, cells were washed with PBS then detached with 182 
PBS/EDTA (5 mM) and lysed in  TNE buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 5 183 
mM EDTA, 0.5% Triton X-100, 0.5%) containing protease inhibitors for 1 hour at 4 °C under 184 
gentle agitation. Lysates were clarified by centrifugation at 14 000 rpm for 15 minutes at 4 oC 185 
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and the supernatants were mixed with sample buffer 4X to obtain a final concentration of 1X 186 
SDS-PAGE loading buffer (62.5 mM Tris-HCl pH 6.5, 2.5% SDS, 10% glycerol, 0.01% 187 
bromophenol blue). Proteins were then resolved on SDS-PAGE, transferred to nitrocellulose 188 
membranes and detected by immunoblotting using the indicated antibody. 189 
Immunofluorescence, image analysis and quantification 190 
 191 
COS-7 or HeLa cells were grown on glass coverslips for 24 hours and co-transfected with 192 
CLN5-HA and PSAP-CLN5-myc. 24 hours post-transfection, cells were fixed with 4 % 193 
paraformaldehyde in PBS for 15 min. Cells were subsequently incubated with polyclonal anti-194 
HA and monoclonal anti-myc antibodies at 1:1000 dilutions in 0.1% BSA, 0.5 % saponin in PBS 195 
for 2 hours. Following two 5 min washes with PBS, the cells were incubated with anti-mouse 196 
AlexaFluor 488 and anti-rabbit AlexaFluor 594 for 1h in the same buffer as above. After two 5 197 
min washes in PBS, the coverslips were mounted on slides using Fluoromount-G 198 
(SouthernBiotech, Birmingham, AL,) and imaged using an inverted microscope Olympus IX71 199 
equipped with a confocal module (Thorlabs, Newton, NJ). Co-localization was assessed using 200 
the method described in [31, 32] using scripts programmed in Matlab (Mathworks, Natick, MA). 201 
First, thresholds for both channels are determined automatically so as the pixel intensity above 202 
them has positive Pearson’s linear correlation coefficient. Finally, the co-localization is defined 203 
as the fraction of intensity in the HA channel that co-localizes with the myc channel above the 204 




HA tagged CLN5 is glycosylated and cleaved into mature CLN5. 209 
 210 
Prediction tools such as TOPCONs (http://topcons.cbr.su.se/) routinely find at least one 211 
transmembrane (TM) domain in CLN5 from residues 73 - 93 based on the 407 amino acid 212 
protein (Fig. 1A). CLN5 is first translated as a 407 amino acid protein with a predicted 213 
transmembrane domain (Fig. 1A, yellow box), while in lysosomes, CLN5 is found as a soluble 214 
luminal protein [8, 13]. In order to understand the translation and processing of CLN5, we 215 
expressed HA-CLN5 and CLN5-HA in HeLa cells and performed a Western blot (Fig. 1B). For 216 
HA-CLN5, we found bands slightly below 50 kDa (Fig. 1B, open arrowhead), slightly above 75 217 
kDa (Fig. 1B, solid arrow) and slightly below 20 kDa (Fig. 1B, closed arrowhead). These bands 218 
correspond to uncleaved, unglycosylated CLN5 (preproCLN5, predicted molecular mass of 46.3 219 
kDa, open arrowhead), uncleaved, glycosylated CLN5 (proCLN5, solid arrow) and the cleaved 220 
N-terminal fragment (ntfCLN5, solid arrowhead). When we expressed CLN5-HA, we found 221 
almost exclusively one band, slightly above 50 kDa (Fig. 1B, open arrow), corresponding to 222 
cleaved and glycosylated mature CLN5 (mCLN5, open arrow) with a small fraction of proCLN5 223 
(Fig. 1B, solid arrow). To confirm that that preproCLN5 (open arrowhead) is the unglycosylated 224 
form of CLN5, we treated samples with either EndoH or PNGase F (Fig. 1C). As expected, 225 
EndoH or PNGase F treatment did not affect the molecular weight of preproCLN5, whereas 226 
proCLN5 was entirely converted in preproCLN5 after deglycosylation (Fig. 1C). We also 227 
observed a shift in molecular weight corresponding to the deglycosylated form of the mature 228 
protein in samples containing CLN5-HA. As predicted the band corresponding to preproCLN5 229 
remained unchanged in all samples (Fig. 1C). These data suggest that HA tagged CLN5 can be 230 
glycosylated and cleaved in a similar fashion to endogenous CLN5. 231 




CLN5 is initially translated as a type II transmembrane protein. 233 
 234 
Recently, using a topology assay on isolated microsomal fractions, CLN5 was found to 235 
contain at least 1 transmembrane domain [21]. To confirm these results, we performed a 236 
topology assay in perforated intact cells rather than on isolated microsomal membranes. We 237 
expressed HA-CLN5, CLN5-HA, a soluble lysosomal protein, prosaposin-myc (PSAP-myc,) and 238 
a type I transmembrane protein (sortilin-myc) in HeLa cells. Following permeabilisation with 239 
digitonin, which induces pore formation in the plasma membrane but leaves internal membranes 240 
intact preventing the trypsin from digesting proteins within the lumen of organelles, the cells 241 
were incubated in cold diluted tryspin solution. As predicted, we found that PSAP-myc was not 242 
digested, while the cytosolic C-terminal tail of sortilin-myc was (Fig. 2A). We found that the N-243 
terminal tail of CLN5 was digested (Fig. 2A) suggesting that it was in the cytosol and therefore 244 
accessible to tryspin. Conversely, mature CLN5 appears to be a soluble protein within the lumen 245 
of organelles as it was protected from tryspin digestion (Fig. 2A). This data supports a model that 246 
preproCLN5 (unglycosylated) and proCLN5 (glycosylated) are type II transmembrane proteins 247 
cleaved into a mature soluble protein.   248 
Next, we performed a membrane separation assay to determine which form of CLN5 was 249 
membrane bound and which was soluble [30]. As preproCLN5 and proCLN5 presumably reside 250 
in the early secretory pathway, we focused our analysis using endoplasmic reticulum (ER) 251 
localized proteins. Our membrane separation was successful as the integral membrane protein 252 
calnexin was found almost exclusively in the membrane fraction (Fig. 2B) while the cytosolic 253 
protein -tubulin was found in the cytosolic fraction (Fig. 2B). The soluble ER protein BiP was 254 
found in the membrane fraction, suggesting that our assay was isolating intact ER membranes 255 
(Fig. 2B). We found that the majority of HA-CLN5 was associated with the membrane fraction 256 
while a very small amount, was present in the soluble fractions (Fig. 2B). This suggested that 257 
preproCLN5 and proCLN5 are membrane associated and combined with data from our topology 258 
assay (Fig. 2A), supports the conclusion that preproCLN5 and proCLN5 are type II 259 
transmembrane domain proteins. Next we performed the assay using two truncated variants of 260 
CLN5 found in human disease, CLN5Y392* and CLN5W75*, which correspond to the Finnish major 261 
mutation leading to a protein of 391 amino acids [18] and Finnish minor variant of the protein 262 
that leads to a truncated protein of 75 amino acids (truncated prior to its predicted 263 
transmembrane domain) [18]. As with wild-type protein, we found that HA-CLN5Y392* was 264 
significantly in the membrane fraction with very little found in the soluble fraction. This result 265 
suggests that the Finnish major mutant is initially translated as a transmembrane protein. In the 266 
case of the Finnish minor mutant, we found that HA-CLN5W75* was no longer associated with 267 
membranes and found most of the protein in the soluble fraction. The loss of membrane 268 
association infers that the first 75 amino acids comprised of the N-terminal region are not 269 
sufficient for CLN5 membrane interaction or for its internalization into the lumen of organelles 270 
suggesting that this region does not contain a signal peptide. Our results strongly suggest wild-271 
type preproCLN5, proCLN5 and proCLN5Y392* are integral membrane proteins. We next 272 
performed a membrane separation assay using CLN5-HA. As expected, when internal 273 
endosomal and lysosomal membranes are left intact, CLN5-HA is found in the membrane 274 
fraction suggesting that mCLN5 is found within a membrane compartment, presumably the 275 
lysosomal compartment (Fig. 2C). However, when membranes are linearized with Na2CO3, 276 
CLN5-HA, along with the soluble lysosomal proteins cathepsin D and prosaposin-myc, are 277 
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released into the soluble fraction (Fig. 2C). This result is in stark contrast to a previous 278 
publication showing that mCLN5 is tightly membrane bound [21]. However, in that study, 279 
internal soluble lysosomal proteins such as cathepsin D and prosaposin were not used as control, 280 
so it is possible that the NA2CO3 treatment used was not sufficient to rupture internal membranes 281 
or that their centrifugation protocol lead to the isolation of protein complexes. Our data strongly 282 
supports our hypothesis that preproCLN5 and proCLN5 are transmembrane forms of CLN5 and 283 
that mCLN5 is a soluble protein found inside the lumen of organelles.  284 
 285 
CLN5 is cleaved after residue arginine 92 to produce a soluble mature protein. 286 
 287 
It is clear that proCLN5 is cleaved to produce a mature soluble protein. The exact site of 288 
cleavage has never been determined although experimental evidence points to residue 96 [8]. To 289 
verify whether or not cleavage occurs at residue 96, we expressed CLN5-HA in HEK 293T cells 290 
and purified the protein using immunoprecipitation with anti-HA antibodies and performed mass 291 
spectrometry analysis on the purified band (Fig. 3A). A list of the peptides recovered with their 292 
corresponding abundance is shown (Fig. 3B). Mass spectrometry analysis identified CLN5 293 
fragments beginning from residue 93 suggesting that CLN5 is cleaved prior to this residue. 294 
Mouse CLN5 is thought to consist of only 358 amino acids rather than the 407 found in humans 295 
[33]. In this shorter form, SignalIP 4.1 (http://www.cbs.dtu.dk/services/SignalP/) predicts a 296 
cleavage site at precisely between arginine 92 and valine 93 that was not predicted in the 407 297 
amino acid form of the protein. Furthermore, as these two amino acids are the predicted to be 298 
near the membrane interface with the organelle lumen, it appears that cleavage occurs nears this 299 
interface to release mCLN5. However, due to the nature of the mass spectrometry analysis, we 300 
are not able to completely exclude cleavage at residues upstream from this site, as the smallest 301 
fragment we can recover is 5 amino acids and trypsin digestion for mass spectrometry analysis 302 
cleaves at arginine residues. Therefore, our results support that mature soluble CLN5 appears to 303 
include residues 93 - 407 (Fig. 3C) producing a 314 amino acid mature protein but could 304 
possibly include residues 89 - 407. Other analysis would be required to resolve this discrepancy.   305 
 306 
CLN5 cleavage is inhibited by (Z-LL)2-ketone. 307 
 308 
Since proCLN5 is a type II transmembrane protein and cleavage occurs within the 309 
membrane, we treated cells with (Z-LL)2-ketone that is known to inhibit the function of most of 310 
the SPP/SPPL family members who are known to cleave type II transmembrane domain proteins 311 
[23]. We tested the effects of (Z-LL)2-ketone and other inhibitors on the processing of CLN5 312 
from proCLN5 with an apparent molecular weight above 75 kDa to mature CLN5 (mCLN5) with 313 
a molecular weight above 50 kDa. We tested leupeptin (a cysteine, serine and threonine 314 
peptidases inhibitor), pepstatin (an aspartyl protease inhibitor), E64 (a cysteine protease 315 
inhibitor) and 3 concentrations of (Z-LL)2-ketone (an inhibitor of the SPP/SPPL family) in HeLa 316 
cells transfected with CLN5-HA. We found that only (Z-LL)2-ketone prevented the cleavage of 317 
CLN5 from proCLN5 (Fig. 4A, solid arrow) to mCLN5 (Fig. 4A, open arrow) as the other 318 
inhibitors had no effect (Fig. 4A). To verify that the band appearing at 75kDa was in fact de novo 319 
synthesized proCLN5 that was not cleaved, we performed a cycloheximide chase experiment in 320 
the presence of the inhibitor (Z-LL)2-ketone, this time using both HA-CLN5 and CLN5-HA (Fig. 321 
4B). In cells treated with cycloheximide, we found no proCLN5 (Fig. 4B, solid arrow) in CLN5-322 
HA transfected cells suggesting that the band appearing at 75 kDa was indeed newly synthesized 323 
CLN5 is cleaved by SPPL3 to produce a soluble protein  
 
  8
proCLN5 that was not processed to mCLN5. Since CLN5 was not processed in (Z-LL)2-ketone 324 
treated cells, we hypothesized that HA-CLN5 would not be cleaved and we would therefore 325 
expect an increase in the proCLN5 at 75 kDa and a decrease in the N-terminal cleaved fragment 326 
below 20 kDa. We found an increase in proCLN5 in the cells expressing HA-CLN5 treated with 327 
the (Z-LL)2-ketone (Fig. 4B, solid arrow), but to our surprise, we also found more of the N-328 
terminal fragment (ntf) (Fig. 4B, solid arrowhead), suggesting that SPP/SPPL proteases could 329 
also be involved in the cleaving and degradation of the N-terminal fragment (ntf) by generating 330 
an intracellular domain (icd) that could be degraded by the proteasome. To test if the cleavage of 331 
ntfCLN5 into an icdCLN5 fragment leads to its degradation, HeLa cells were transfected with 332 
HA-CLN5 and treated with different concentrations or a fixed concentration for different 333 
amounts of time with the proteasome inhibitor MG132. ntfCLN5 was visible as a slight band in 334 
non-treated cells (Fig 4C). Treatment with MG132 dramatically increased the level of a band 335 
slightly smaller than ntfCLN5 suggesting the possibility of a further cleavage event (Fig. 4C, 336 
solid arrowhead) even though it had very little effect on the preproCLN5 (Fig. 4C, open 337 
arrowhead) and proCLN5 (Fig. 4C, solid arrow). Moreover, a significant increase in the level of 338 
the new band is already observable after only 30 min of MG132 treatment, showing that this new 339 
cleavage product is rapidly degraded (Fig. 4C, solid arrowhead, right panel). We hypothesized 340 
that the higher molecular weight fragment was ntfCLN5 within the membrane, while the smaller 341 
fragment, icdCLN5, was cleaved from ntfCLN5 and degraded in the proteasome. To test this 342 
experimentally, we performed a membrane assay on HeLa cells that had been transfected with 343 
HA-CLN5 and treated with MG132 (Fig. 4D, solid arrow). Indeed, we found the higher 344 
molecular weight ntfCLN5 in the membrane fraction (M), while in the cytosolic fraction (C), we 345 
found icdCLN5 that was not degraded due to the MG132. This suggests that ntfCLN5 is further 346 
cleaved resulting in the release of a soluble icdCLN5 that is subsequently rapidly degraded by 347 
the proteasome.  348 
 349 
SPPL3 cleaves proCLN5 into mCLN5 in the early secretory pathway. 350 
 351 
Several mutations are thought to retain CLN5 in the early secretory pathway [34], 352 
including R112P [8]. In at least 4 mutations that result in the retention of the protein, CLN5 is 353 
still cleaved into mCLN5 suggesting cleavage occurs prior to exit from the Golgi apparatus [7]. 354 
First, we performed a Western blot to determine the cleavage pattern of HA-CLN5, HA-355 
CLN5R112P, CLN5-HA and CLN5R112P-HA. We found that HA-CLN5R112P and CLN5R112P-HA 356 
showed the same expression pattern, glycosylation (based on molecular mass) and processing as 357 
HA-CLN5 and CLN5-HA (Supp. Fig 1), suggesting that cleavage occurs in the early secretory 358 
pathway prior to Golgi exit of mCLN5. 359 
The members of the SPP/SPPL family of proteases function at various intracellular 360 
locations. As such, SPP and SPPL2c are localized to the ER, SPPL2a is found in the lysosomal 361 
compartment [35], SPPL2b at the plasma membrane and SPPL3 is localized to the ER and Golgi 362 
apparatus [23, 36]. Most SPP/SPPL family members require cleavage by a sheddase prior to their 363 
function [27]. Since cleavage from proCLN5 to mCLN5 was inhibited by (Z-LL)2-ketone, it is 364 
most likely performed by a member of the SPP/SPPL family or a protease/protease cascade that 365 
is activated by a member of the SPP/SPPL family. SPPL3 has been shown to function without 366 
the requirement for prior cleavage by a sheddase [26]. Therefore, in order to test whether SPPL3 367 
is the protease implicated in cleaving proCLN5 to mCLN5, we co-transfected HeLa cells with 368 
CLN5-FLAG and either wild-type HA-SPPL2b, HA-SPPL3 or their catalytically inactive forms 369 
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(HA-SPPL2bD421A and HA-SPPL3D272A). 24-hours post-transfection, we performed a Western 370 
blot using antibodies to either FLAG or HA. CLN5-FLAG was cleaved to mCLN5 in the cells 371 
co-transfected with HA-SPPL2b, HA-SPPL2bD421A and HA-SPPL3 (Fig. 5A, open arrow). 372 
However, in cells co-transfected with HA-SPPL3D272A, we found an accumulation of proCLN5 373 
not found in the other co-transfections (Fig. 5A, solid arrow). To confirm this data, we depleted 374 
SPPL3 from HEK 293T cells using siRNA. The depletion of SPPL3 was efficient when tested by 375 
Western blotting (Fig. 5B). In cells depleted of SPPL3, we found an accumulation of proCLN5 376 
Fig. 5B, solid arrow) in cell lysates not found in the mock-depleted cells (Fig. 5B). In addition to 377 
a block in cleavage, mCLN5 also appeared at a slightly higher molecular weight most likely due 378 
to hyperglycosylation induced by reduced SPPL3 expression [37].  379 
 380 
CLN5 does not contain a classic signal sequence 381 
 382 
Classical signal sequences are usually 15 to 20 amino acids long [38] and are usually 383 
cleaved during translation. CLN5 does not appear to have a classical signal sequence as cleavage 384 
occurs after residue 92 and more than likely after insertion into the membrane since we observe 385 
both HA-CLN5 and CLN5-HA by Western blotting. We therefore generated a construct that 386 
switched the N-terminal portion of CLN5 with that of prosaposin (PSAP) fusing residues 1 - 28 387 
of prosaposin with residues 94 - 407 of CLN5. PSAP is a soluble lysosomal protein whose 388 
trafficking requires sortilin [39]. The N-terminal portion of PSAP contains a classical signal 389 
peptide 16 residues long cleaved from the mature protein presumably by signal peptidase during 390 
translation [40] and not SPPL3 or a related SPPL family member. First, we determined whether 391 
the PSAP/CLN5 chimera would enter the lumen of organelles. We transfected HeLa cells with 392 
PSAP-myc, PSAP/CLN5-myc and CLN5-HA. We found that all 3 constructs entered the 393 
secretory pathway, as expected, as they were localized to the membrane fraction in the standard 394 
assay suggesting that they were luminal proteins (Fig. 5C). Next, we sought to determine 395 
whether or not switching the N-terminal portion of CLN5 for the signal peptide of prosaposin 396 
affected its intracellular distribution. We tested the ability of the PSAP/CLN5-myc (Supp. Fig. 397 
2A, green) chimera to co-localize with CLN5-HA (Supp Fig. 2B, red) in COS-7 and HeLa cells. 398 
COS-7 cells were chosen for their large cytoplasm, allowing for a clearer distinction between 399 
different cytoplasmic organelles. We found the PSAP/CLN5-myc chimera is in the same 400 
structures as CLN5-HA (Supp Fig. 2C) suggesting that the N-terminal portion of CLN5 was not 401 
required for its localization. In fact, co-localization analysis showed that CLN5-HA co-localized 402 
with PSAP/CLN5-myc 96.2% (S.D. +/- 3.1) of the time in COS-7 cells (Supp Fig. 2D, black 403 
bar). Significant co-localization between CLN5-HA and PSAP/CLN5-myc was also observed in 404 
HeLa cells. Image analysis revealed that CLN5-HA co-localized with PSAP/CLN5-myc 96.1% 405 
(S.D. +/- 4.6) of the time (Supp Fig. 2D, white bar). This data suggests that CLN5 is sorted and 406 
transported to the lysosomal compartment post-cleavage by a mechanism independent of its N-407 
terminal fragment. 408 
Next, we tested whether PSAP/CLN5-myc chimera was cleaved by SPPL3. We co-409 
transfected HeLa cells with PSAP/CLN5-myc and HA-SPPL3 or HA-SPPL3D272A and found no 410 
difference in the cleavage of PSAP/CLN5-myc (Fig. 5D). This suggested that the classical signal 411 
peptide of the chimera was cleaved co-translationally by another mechanism, presumably signal 412 
peptidase within the ER and not by SPPL3. Furthermore, this supports a role for SPPL3 in 413 
cleaving CLN5 and not affecting it glycosylation. If the effects observed were due to 414 
glycosylation, expressing wild-type SPPL3 would result in a lower molecular weight band for 415 
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both wild-type CLN5 as well as the PSAP/CLN5 chimera due to decreased glycosylation as 416 
previously observed for other proteins [37]. This indicates that SPPL3 either directly cleaves 417 
CLN5 into proCLN5 and ntfCLN5 after translation and insertion into the membrane as a type II 418 
transmembrane domain or induces its cleavage by activating other proteases.  419 
SPPL3 and SPPL2a/b sequentially cleave the foamy virus envelope protein [32]. 420 
Therefore we tested if SPPL2b and/or SPPL3 cleave ntfCLN5 by overexpressing WT or 421 
catalytically dead forms of these proteins with FLAG-CLN5 in HeLa cells. Overexpression of 422 
HA-SPPL3D272A significantly increased the amount of ntfCLN5 whereas HA-SPPL2bD421A only 423 
had a moderate effect (Fig. 5E, solid arrowhead) suggesting that both these enzyme may be 424 
implicated in the cleavage of ntfCLN5 (Fig. 5E). To verify the existence of the ntfCLN5 and 425 
icdCLN5, we expressed HA-CLN5 in HEK 293T cells and treated the cells with DMSO, 10M 426 
MG132 for 30 minutes, 25 M (Z-LL)2-ketone for 4 hours or co-expressed HA-SPPL3D272A and 427 
performed a Western blot with anti-HA antibody (Figure 5F). In the MG132 treated cells, we 428 
found a band that was slightly smaller (icdCLN5) than the band recovered in the (Z-LL)2-ketone 429 
treated cells or cells expressing HA-SPPL3D272A (ntfCLN5). This suggests that SPPL3 and 430 
possibly other SPPL family members are implicated in the cleavage of ntfCLN5 to icdCLN5, 431 




Several conclusions can be drawn from the data presented in this paper. First, we 436 
confirmed that CLN5 is initially translated as a type II transmembrane protein in intact cells and 437 
is subsequently cleaved into a mature soluble protein. Second, we demonstrate that a member of 438 
the SPP/SPPL family, most likely SPPL3 mediates this cleavage after residue 92. Finally, we 439 
show that the N-terminal fragment is not implicated in the intracellular localization of CLN5 and 440 
is further processed by members of the SPP/SPPL family, to allow its degradation in the 441 
proteasome. 442 
CLN5 contains a hydrophobic region that is predicted to be a transmembrane domain 443 
between residues 73 and 93. A previous study using isolated microsomes found CLN5 is a type 444 
II transmembrane domain protein [21]. We confirmed this result using a topology assay in intact 445 
cells gently permeabilised with digitonin enabling us to test the topology of CLN5 without 446 
isolating microsomes using high-speed centrifugation, leaving CLN5 in a more physiological 447 
condition. We found that preproCLN5 and proCLN5 are type II transmembrane domain proteins 448 
while mature CLN5 (mCLN5) is within the lumen of organelles and localizes to the lysosomal 449 
compartment. A recent study also demonstrated a further processing step as mCLN5 is processed 450 
in the lysosomal compartment as leupeptin blocked this final processing step [41]. Next to 451 
determine whether mCLN5 was soluble or membrane bound, we performed a Na2CO3 extraction 452 
and found that a significant portion of mCLN5 is soluble. This result differs from a previous 453 
publication that found mCLN5 to be tightly membrane bound [21]. However, those previous 454 
experiments lacked a soluble lysosomal protein as a control. In the previous paper, the authors 455 
showed that two peripheral membrane proteins the endosomal protein EEA1 and the Golgi 456 
GM130 were released into the cytosolic fraction, but not mCLN5. They did not provide direct 457 
evidence that their assay resulted in the release of soluble lysosomal proteins such as cathepsin D 458 
or prosaposin.  459 
The hydrophobic region (amino acids 73 - 93) is not an actual transmembrane domain. It 460 
appears to serve as a signal anchor allowing the insertion of the C-terminal portion of CLN5 461 
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(amino acids 93 - 407) into the lumen of the ER [40]. Once inserted into the membrane, CLN5 is 462 
subsequently cleaved by a member of the SPP/SPPL protease family or a protease that is 463 
activated by one of these intramembrane aspartyl proteases. Our observation of the 2 forms of 464 
CLN5 depending on the placement of the HA tag (HA-CLN5 versus CLN5-HA) would suggest 465 
that cleavage of the overexpressed protein occurs inefficiently or after translocation and 466 
membrane insertion. If cleavage, under physiological conditions were also inefficient, it would 467 
be possible that CLN5 as a type II transmembrane protein could have biological activity in the 468 
ER or early Golgi, or that ntfCLN5 could have a biological function.  469 
To identify the mechanism of cleavage of CLN5, we treated cells with a variety of 470 
inhibitors including (Z-LL2)-ketone, which was previously shown to inhibit the SPP/SPPL, 471 
which specifically cleave type II transmembrane proteins. Not only did the inhibitor prevent 472 
cleavage from proCLN5 to mCLN5, it also blocked the degradation of ntfCLN5. Using 473 
catalytically dead mutants of SPPL2b and SPPL3, we found that SPPL3 affects the cleavage 474 
from proCLN5 to mCLN5, but SPPL2b does not. This is consistent with previous observations 475 
showing that SPPL3 is the only member of the SPPL family that does not require prior shedding 476 
for proteolysis [32]. However, SPPL3 is also capable of regulating cellular glycosylation 477 
processes, by cleavage of various glycosyltransferases [37]. This could also potentially account 478 
for the altered molecular weight of mCLN5 upon SPPL3 knock down. 479 
SPPL3 is also capable of cleaving ntfCLN5 but our results suggest that SPPL2b and 480 
maybe another member(s) of the SPP/SPPL family could also be involved in the cleavage of 481 
ntfCLN5. Presumably, the cleavage of ntfCLN5 leads to its degradation as inhibition of the 482 
proteasome with MG132 rapidly increases the level of ntfCLN5. It is unclear at this point if 483 
ntfCLN5 has a cellular function but it does not appear to be implicated in the localization of 484 
CLN5 as replacing the N-terminal portion of CLN5 with the signal peptide of prosaposin, did not 485 
appear to affect it intracellular distribution. In fact, we found that CLN5-HA and PSAP/CLN5-486 
myc co-localized more than 95% of the time within cells. However, based on our data, it appears 487 
that the ntf of CLN5 is a signal anchor and not a classical signal peptide. This is supported by 488 
previous work highlighting the cleavage site of GFP-CLN5 expressed in cells [8].     489 
CLN5 most likely represents an additional novel SPPL3 substrate. However, we cannot 490 
fully exclude that SPP/SPPL proteases activate other proteases that cleave CLN5 in the ER/Golgi 491 
to generate its soluble variant mCLN5. Using mass spectrometry analysis of purified mature 492 
CLN5, we were able to identify the site of cleavage after residue 92, which is the predicted 493 
cleavage site of mouse CLN5. In mice and some other species, CLN5 is though to be 358 amino 494 
acids long, while in humans the longest form is 407 amino acids. ntfCLN5 in mice is predicted to 495 
be 42 amino acids with a predicted cleavage site between residues 42 and 43. This would be a 496 
highly usual signal peptide in terms of length, and may well be a target of SPPL3, but at this time 497 
we are not able to eliminate this possibility. Contrary to other aspartic proteases, no consensus 498 
cleavage sequence has been described for the SPP family of proteases. It has been suggested that 499 
the α-helical conformation of transmembrane domains (TMDs) hides peptide bonds from 500 
proteases and that intramembrane proteolysis requires the presence of helix destabilizing amino 501 
acids in the TMD. Indeed, reducing the α-helical content of the Bri2 TMD increases its cleavage 502 
by SPPL2b [25]. We have confirmed that in contrast to other SPP proteases, SPPL3 cleaves full-503 
length proteins without prior shedding. Consequently, its mechanism of substrate recognition is 504 
likely to differ from other SPPs and further mutational analysis is required to identify the 505 
structural determinants responsible for the cleavage specificity.  506 
 507 




In conclusion, we have shown that SPPL3 directly or indirectly mediates the cleavage of 509 
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Figure 1: HA tagged CLN5 is cleaved and glycosylated. 643 
(A) Schematic representation of CLN5 tagged at the N-terminal end (HA-CLN5) or the C-644 
terminal end (CLN5-HA). Highlighted in yellow is the hydrophobic region predicted to be a 645 
possible transmembrane domain (residues 73-93). proCLN5 is represented as the full-length 646 
protein composed of 407 amino acids (solid arrow), the cleaved N-terminal fragment (ntfCLN5, 647 
solid arrow head) and mature CLN5 (mCLN5, open arrow). (B) HeLa cells were transfected with 648 
HA-CLN5 or CLN5-HA. 24 hours post-transfection, the cells were lysed in TNE and the 649 
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samples run on a 12% SDS-PAGE and analyzed by Western blot (Wb) with an antibody against 650 
HA. The bottom of the gel was overexposed to increase the visibility of the N-terminal fragment 651 
(ntfCLN5). The solid arrow indicates proCLN5 (fully glycosylated), solid arrowhead indicates 652 
ntfCLN5open arrow indicates mCLN5 and the open arrowhead represents preproCLN5 653 
(unglycosylated). (C) HeLa cells were transfected with HA-CLN5 or CLN5-HA. 24 hours post-654 
transfection, the cells were lysed in TNE and the cell lysates were treated with either EndoH or 655 
PNGase F and subsequently run on SDS-PAGE and Western blotted (Wb) with anti HA 656 
antibodies.  657 
 658 
Figure 2: CLN5 is a type II transmembrane protein cleaved to a soluble protein. 659 
(A) HeLa cells were transfected with HA-CLN5, CLN5-HA, prosaposin-myc (PSAP-myc) or 660 
sortilin-myc. 24 hours post-transfection, cells were split into 3 groups. In group 1, the cells were 661 
lysed in TNE. In group 2, cells were treated with 20 mM digitonin in KHM buffer on ice for 10 662 
min prior to lysis. In group 3, cells were treated with digitonin followed by a 30 min treatment 663 
with trypsin diluted in KHM on ice prior to lysis. (B) HeLa cells were transfected with HA-664 
CLN5, HA-CLN5Y392* or HA-CLN5W75*. 24 hours post- transfection, a membrane separation 665 
assay (see materials and methods) was performed. Equal volumes of cytosolic and membrane 666 
fractions were run on a 12% SDS-PAGE and then analyzed by Western blot (Wb). Nitrocellulose 667 
membranes were sequentially stained with the following antibodies: mono-HA, poly-calnexin 668 
(an ER transmembrane protein), poly-BiP (a soluble ER protein) and poly--tubulin (a cytosolic 669 
protein) C: soluble cytosolic fraction, M: membrane fraction. (C) Cells were transfected with 670 
either HA-CLN5 or CLN5-HA and membranes were isolated by performing a membrane 671 
separation assay or sodium carbonate assay (see material and methods). Nitrocellulose 672 
membranes were sequentially stained with the following antibodies: mono-HA, and poly-Lamp2 673 
(a lysosomal transmembrane protein), mono-myc and poly-cathepsin D (proCatD = proCathepsin 674 
D, mCatD = mature Cathepsin D).  C: cytosolic fraction, M: membrane fraction.  675 
 676 
Figure 3: CLN5 is cleaved after residue 92 677 
(A) HEK 293T cells were transfected with CLN5-HA. 48 hours post-transfection, the cells were 678 
lysed in TNE and an immunoprecipitation with anti-HA antibody was performed. The post-IP 679 
protein eluted from the sepharose beads was run on SDS-PAGE and coomassie stained. (B) The 680 
band from A was cut out of the gel and sent for mass spectroscopy analysis at the proteomics 681 
facility of the Institute for Research in Immunology and Cancer (IRIC), University of Montreal. 682 
The CLN5 fragments recovered are listed with their abundance. (C) CLN5 amino acids sequence 683 
with the residues detected by mass spectrometry highlighted in green. This suggests that CLN5 is 684 
cleaved after residue 92 (red box) to produce a mature soluble protein. (D) HeLa cells were 685 
transfected with various arginine mutants of CLN5 to test if these residues were required for 686 
cleavage. 24 hours post-transfection, the cells were lysed in TNE and an SDS-PAGE was 687 
performed. Western blotting (Wb) with anti-HA was done. 688 
 689 
Figure 4: (Z-LL)2-Ketone prevents the cleavage of proCLN5 to mCLN5 690 
(A) HeLa cells were transfected with CLN5-HA and subsequently treated with leupeptin, 691 
pepstatin, E64 or (Z-LL)2-ketone at the concentration indicated for either 0, 3 or 6 hours. 692 
Following cell lysis, the lysates were run on a 12% polyacrylamide gel, transferred to 693 
nitrocellulose and blotted (Wb) with anti-HA antibody. (B) HeLa cells were transfected with 694 
either HA-CLN5 or CLN5-HA and treated with (Z-LL)2-ketone with or without cycloheximide 695 
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for 0, 3 or 6 hours. Total cell lysate was subsequently run a 12% SDS-PAGE and Western 696 
blotted (Wb) with anti-HA or anti-actin antibody. (C) HeLa cells were transfected with HA-697 
CLN5 and treated with the indicated concentrations of MG132 for 4hrs (left panel) or with 5 μM 698 
MG132 for the indicated time periods (right panel). Total cell lysate was subsequently run a 12% 699 
SDS-PAGE and Western blotted (Wb) with anti-HA. (D) HeLa cells were transfected with HA-700 
CLN5. 24Hrs post-transfection, cells were treated (+MG132) with 5m MG132 for 1 hour and a 701 
membrane assay was performed. The cytosolic fraction and membrane fraction were run on a 702 
12% polyacrylamide gel and Western blotting (Wb) performed with anti-HA antibody. C: 703 
cytosolic fraction, M: membrane fraction.  704 
 705 
Figure 5: SPPL3 cleaves proCLN5 to mCLN5 706 
(A) HeLa cells were co-transfected with CLN5-Flag and HA-SPPL2b, HA-SPPL2bD421A, HA-707 
SPPL3 or HA-SPPL3D272A. 24 hours post-transfection, cells were lysed in TNE and samples run 708 
on a SDS-PAGE. Western blotting (Wb) was performed with anti-FLAG and anti-HA 709 
antibodies. (B) siRNA was used to deplete SPPL3 in HEK 293T. Cells were transfected with 710 
HA-CLN5 and a Western blot (Wb) was performed with anti-CLN5 and anti-SPPL3 antibodies. 711 
Wb of calnexin was used as a loading control.  (C) HeLa cells were transfected with PSAP-myc, 712 
PSAP/CLN5-myc or CLN5-HA. A membrane separation assay was performed to determine their 713 
distribution. C: cytosolic fraction, M: membrane fraction. (D) HeLa cells were co-transfected 714 
with PSAP/CLN5-myc and HA-SPPL3 or HA-SPPL3D272A. 24 hours post-transfection, cells 715 
were lysed and run on SDS-PAGE followed by Western blotting (Wb) with anti-myc and anti-716 
HA antibodies. (E) HeLa cells were co-transfected with Flag-CLN5 and HA-SPPL2b, HA-717 
SPPL2bD421A, HA-SPPL3 or HA-SPPL3D272A. 24 hours post-transfection, cells were lysed in 718 
TNE and samples run on a SDS-PAGE. Western blotting (Wb) was performed with anti-FLAG 719 
and anti-HA antibodies. (F) HEK 293T cells were transfected with HA-CLN5 and treated with 720 
DMSO, 10M MG132 for 30 minutes, 25 M (Z-LL)2-ketone for 4 hours or co-expressed HA-721 
SPPL3D272A. Total cell lysates were run on a 12% polyacrylamide gel and a Western blot (Wb) 722 
with anti-HA antibody was performed. (G) Schematic representation of the cleavage of proCLN5 723 
after membrane insertion by SPPL3 into mCLN5 and ntfCLN5. icdCLN5 is cleaved from 724 
ntfCLN5 and degraded by the proteasome.  725 
 726 
Supplemental Figure 1: CLN5R112P is processed like wild-type CLN5. 727 
HeLa cells were transfected with HA-CLN5, HA-CLN5R112P, CLN5-HA or CLN5R112P-HA. 24 728 
hours post-transfection, cells were lysed and run on a SDS-PAGE. Western blotting (Wb) was 729 
performed with anti-HA antibody. 730 
 731 
Supplemental Figure 2: The N-terminal tail of CLN5 is not required for its localization. 732 
(A - C) COS-7 cells grown overnight on glass coverslips were transfected with CLN5-HA and 733 
PSAP/CLN5-myc, fixed in 4% paraformaldehyde and immunostained with monoclonal anti-myc 734 
(A, green) and polyclonal anti-HA (B, red) antibodies. The merge of the image is shown in C. 735 
Scale bar = 10m. (D) Protein co-localization was quantitatively analyzed in COS-7 and HeLa 736 
cells. 44 and 41 cells were analyzed respectively. Error bar represents standard deviation.   737 







